Louisiana to receive nearly $7M in EpiPen settlement

Epipen settlement 09.12.17_1505238025552.PNG

Louisiana is among several states that will receive millions of dollars from an EpiPen settlement. 

Drug manufacturer Mylan, Inc. was accused of knowingly overcharging taxpayers for EpiPen® and EpiPen Jr.® dispensed to Medicaid beneficiaries.

Per the agreement, Mylan will pay $465 million to the federal government and the states.

Attorney General Jeff Landry announced Tuesday that Louisiana’s portion is $6.9 million and it will go toward replenishing the State’s Medicaid program.

General Landry said, “As I have said before, all welfare fraud needs to be found and ended. From providers to beneficiaries, those who defraud our State’s Medicaid welfare program steal our taxpayers’ money and jeopardize care for our most vulnerable.  People and businesses who deceive the hard-working taxpayers of Louisiana should be held accountable for their actions. I will do all that I legally can to ensure Medicaid fraudsters are brought to justice.”

From July 29, 2010 to March 31, 2017, Mylan allegedly submitted false statements to the Centers for Medicare and Medicaid Services that incorrectly classified EpiPen as a “non-innovator multiple source” drug, as opposed to a “single source” or “innovator multiple source” drug.

Mylan also allegedly did not report a Best Price to CMS for EpiPen, which it was required to do for all “single source” and “innovator multiple source” drugs.

As a result, Mylan submitted or caused false statements to be submitted to CMS and/or the States relating to EpiPen for Medicaid rebate purposes and underpaid its EpiPen rebates to the State Medicaid Programs. 

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


More Check This Out
Loving Living Local 600x600

Don't Miss